Reference:
  1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
  2. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28: 1133-1140.
  3. Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011; 34: e133.
  4. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249-253
  5. Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 2014; 8: 24-28.
  6. García M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016; 41: 368-370.
  7. Béné J, Moulis G, Bennani I, et.al. French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016; 175: 296-301.
  8. Benzaquen M, Borradori L, Berbis P, et.al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 2018; 78: 1090-1096.
  9. Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.JAMA Dermatol 2018; 154: 1152-1158.
  10. Varpuluoma O, Försti AK, Jokelainen J, et.al. Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study. J Invest Dermatol 2018; 138: 1659-1661.
  11. Izumi K, Nishie W, Mai Y, et.al. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J Invest Dermatol 2016; 136: 2201-2210.
  12. Patsatsi A, Kyriakou A, Meltzanidou P, et.al. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid? Eur J Dermatol2018; 28: 711-713.
  13. Lindgren O, Varpuluoma O, Tuusa J, et.al. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. Acta Derm Venereol Mar 2019; doi: 10.2340/00015555-3166. [Epub ahead of print]
  14. Kasperkiewicz M, Zillikens D The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.
  15. Ujiie H, Muramatsu K, Mushiroda T, et.al. HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol 2018; 138: 1201-1204.
  16. Aso Y, Fukushima M, Sagara M, et.al. (2015) Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract 110: 250-256.
  17. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. (2008) Regulatory T cells and immune tolerance. Cell 133: 775-787.
  18. Muramatsu K, Ujiie H, Kobayashi I, et.al. (2018) Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J Allergy Clin Immunol142: 1818-1830.
  19. Forssmann U, Stoetzer C, Stephan M, et.al. (2008) Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 181: 1120-1127.